Fairlawn Aesthetic MD

JANUARY 10, 2025

If you are looking for an effective way to treat erectile dysfunction, the innovative OrthoGold Acoustic Wave Therapy at Fairlawn Aesthetic MD may be the ideal solution for you. This non-invasive therapy is designed to increase blood flow in the penis, resulting in stronger, more sustainable erections.

Therapy 28

Therapy Sustainability Safety Innovations 28

The Dermatology Digest

DECEMBER 4, 2024

Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for Restem’s umbilical cord outer lining stem cells (ULSCs) program for the treatment of dermatomyositis (DM) and polymyositis (PM). The estimated incidence of PM/DM is approximately 5 to 22 cases per 100,000 individuals. PHOTO CREDIT: DermNet The post U.S.

Treatments 36

Treatments Office Therapy Clinic 36

Alison Bladh

JANUARY 16, 2025

Safety and Precautions While saw palmetto is generally safe, there are a few important considerations to keep in mind: Potential Side Effects Mild digestive issues such as nausea, diarrhoea, or constipation may occur. Interactions Saw palmetto may interact with hormonal therapies, including birth control or hormone replacement therapy (HRT).

Extractions 98

Extractions Management Consultation Consultations 98

The Dermatology Digest

FEBRUARY 18, 2025

Food and Drug Administration (FDA) approved mirdametinib (Gomekli, SpringWorks) for the treatment of adult and pediatric patients aged two and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) that are not amenable to complete resection. Gomekli is an oral, small molecule MEK inhibitor.

Networking 64

Networking Safety Innovations Management 64

The Dermatology Digest

APRIL 7, 2024

A newly developed therapeutic ladder can help guide dermatologists and patients on the use of nonsteroidal treatment options for atopic dermatitis (AD). Nonsteroidal treatment options for AD have rapidly expanded in recent years with the development of phosphodiesterase-4 inhibitors, biologics, and Janus kinase (JAK) inhibitors.

Treatments 77

Treatments Dermatitis Therapy Medical 77

The Dermatology Digest

MARCH 5, 2025

first pivotal Phase 3 Spongilla Treatment for Acne Research (STAR-1) trial of Xyngari, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. The XYNGARI Phase 3 STAR-1 clinical study will evaluate the efficacy, safety, and tolerability of Xyngari in patients with moderate-to-severe facial acne.

Treatments 36

Treatments Rosacea Pores Office 36

Aesthetics Exposed

MARCH 22, 2019

Lasers and light therapies are among the most commonly used devices in the esthetic industry. Modern day usage of light has broadly expanded the range of cosmetic medical treatments. There are three main types of light therapy used in esthetics: LED, IPL and lasers. What is Light? Light behaves as both a particle and a wave.

Hair Removal 195

Hair Removal Esthetics Collagen Rosacea 195

The Dermatology Digest

MARCH 8, 2025

The Phase 3 TRuE-PN clinical trial program comprises TRuE-PN1 and TRuE-PN2 studies, which evaluate the safety and efficacy of twice-daily ruxolitinib cream 1.5% vs. vehicle control achieved an Investigator’s Global Assessment for Stage of Chronic Prurigo Treatment Success (IGA-CPG-S-TS) at Week 12 (15.8% vs. 20.6%, respectively).

Safety 36

Safety Clinic Therapy Dermatology 36

American Esthetician Organization

AUGUST 17, 2023

If you’re one of the millions of people living with the frustrating and persistent redness and bumps of rosacea, you may have already tried a multitude of treatments. However, there’s a new contender in the field of rosacea treatments that’s gaining momentum – laser therapy.

Rosacea 88

Rosacea Treatments Medical Management 88

Dermatology Times

JULY 4, 2024

The experts discuss combination therapy approaches, safety considerations, and targeted interleukin-17 systemic treatments for plaque psoriasis.

Safety 36

Safety Therapy Treatments 36

The Dermatology Digest

MARCH 10, 2025

” The safety profile was consistent with the known safety profile of tildrakizumab, and no serious adverse events related to ILUMYA treatment occurred in this clinical trial,the study showed. .

Pharmaceutical 36

Pharmaceutical Safety Clinic Injections 36

Dermatology Times

JANUARY 9, 2024

Experts in dermatology highlight the crucial role of setting treatment response expectations and stress the need for discussions on managing mild plaque psoriasis, highlighting the utilization of systemic therapies in this context.

Safety 77

Safety Education Therapy Management 77

The Dermatology Digest

MARCH 18, 2025

has completed enrollment in its Phase 3 clinical trial evaluating aminolevulinic acid hydrochloride (Ameluz) with photodynamic therapy (PDT) for the treatment of mild to moderate actinic keratoses (AKs) on the extremities, neck, and trunk. They are then followed up for approximately one year after the last PDT treatment.

Treatments 36

Treatments Dermatology Safety Therapy 36

Dermatology Times

JANUARY 8, 2024

Systemic corticosteroids are often used as primary therapy for PG, but alternatives should be considered for their favorable safety profile.

Clinic 78

Clinic Management Safety Treatments 78

The Dermatology Digest

DECEMBER 11, 2024

Despite disappointing efficacy, ANB032 was well tolerated with no safety signals observed, the Company reported. The ARISE-AD study evaluated the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of ANB032 monotherapy in patients with moderate-to-severe AD.

Safety 36

Safety Dermatitis Therapy Dermatology 36

Lipgloss and Aftershave

NOVEMBER 1, 2024

Jenni Nagle, L+A CO-Founder had a CO2 laser treatment and kept an eight day diary of her recovery process! For estheticians and skincare professionals, addressing pigmentation involves understanding and applying a multimodality treatment approach, which combines various techniques to tackle pigmentation through multiple mechanisms.

Chemical Peels 52

Chemical Peels Vitamin C Hyperpigmentation Microneedling 52

The Dermatology Digest

MARCH 17, 2025

The overall safety profile of povorcitinib is consistent with previous data. No new safety signals were observed and both doses were well tolerated. “The positive Phase 3 data highlights the potential of povorcitinib as an effective oral treatment option for people living with HS.

Safety 36

Safety Document Clinic Therapy 36

The Dermatology Digest

FEBRUARY 25, 2025

This announcement follows the successful completion of a Phase I clinical trial involving 40 healthy volunteers, where ruxoprubart demonstrated promising results and a clean safety profile, with no serious adverse events reported.

Safety 36

Safety Therapy Clinic Dermatology 36

The Dermatology Digest

NOVEMBER 30, 2024

Several new therapies are coming down the pike for the treatment of lichen planus, a chronic inflammatory condition that affects an estimated 1% to 2% of the global population, according to a new report from Research and Markets. Incyte is investigating the efficacy and safety of ruxolitinib cream in cutaneous lichen planus.

Pharmaceutical 36

Pharmaceutical Safety Marketing Therapy 36

The Dermatology Digest

MARCH 17, 2025

The multi-center, randomized, double-blind, placebo-controlled, proof-of-concept trial is designed to evaluate the safety and efficacy of EVO301 in approximately 60 adult patients with moderate-to-severe AD. “AD is a highly heterogenous disease, and for this reason, there remains a need for more effective treatments.

Dermatitis 36

Dermatitis Eczema Injections Tools 36

New Age Spa Institute

DECEMBER 18, 2024

Also known as NASI , this private beauty school in Des Plaines, IL offers training programs for professional licensing in esthetics, massage therapy, makeup, and more. Certifications are targeted programs designed to enhance your knowledge and skills in specific areas of esthetics, cosmetology, or massage therapy. Want more info?

Medical 52

Medical Esthetics Legal Continuing Education 52

Dermatology Times

AUGUST 8, 2024

Key opinion leaders examine safety concerns and adverse event trends in psoriasis treatments, discussing how these factors influence decisions to discontinue therapy and transition patients to alternative interventions.

Safety 36

Safety Treatments Therapy 36

The Dermatology Digest

MARCH 10, 2025

Amgen and Kyowa Kirins rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, met its co-primary endpoints and all key secondary endpoints in moderate-to-severe atopic dermatitis (AD) study, the Companies report. In the lower dose group, 16.3% of patients achieved this endpoint, an 8.0%

Dermatitis 36

Dermatitis Safety Office Eczema 36

The Dermatology Digest

MARCH 3, 2025

Vyjuvek (beremagene geperpavec-svdt, or B-VEC) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) who have mutations in the collagen type VII alpha 1 chain (COL7A1) gene, starting from birth. The CHMPs positive opinion includes support for administration of B-VEC in either a health care setting (e.g.,

Therapy 36

Therapy Clinic Hospital Dermatology 36

The Dermatology Digest

AUGUST 20, 2024

Food and Drug Administration (FDA) approved apremilast for the treatment of moderate to severe plaque psoriasis in children and adolescents ages 6 and older who weigh at least 20 kg (44 lb) and are candidates for phototherapy or systemic therapy. Earlier this year, the U.S. sPGA response for Otezla versus 10.8%

Safety 74

Safety Injections Therapy Treatments 74

US Dermatologt Partners

JANUARY 13, 2025

Dr. Desai says, Professional extractions are key to effective acne treatment, especially for patients with clogged pores that dont respond to topical treatments. Acne extractions also make it possible for acne treatments to be more effective because they are able to penetrate into pores more easily.

Extractions 41

Extractions Scarring Pores Chemical Peels 41

Dermatology Times

MARCH 14, 2024

A panel of experts discusses unique needs of patients with skin of color, look at long-term safety and efficacy of emerging oral treatments, and delve into combining topicals with systemic therapies.

Management 74

Management Safety Therapy Treatments 74

The Dermatology Digest

FEBRUARY 10, 2025

The submission will be supported by data from the MissionEB clinical trial investigating CORDStrom as a disease-modifying therapy for treating RDEB in pediatric patients. CORDStrom is a patent-pending, off-the-shelf, advanced mesenchymal stromal cell (MSC) platform developed to treat complex inflammatory diseases.

Hospital 36

Hospital Sustainability Therapy Marketing 36

The Dermatology Digest

NOVEMBER 6, 2024

This award was established this year to accelerate the translation of research into potential treatments and diagnostics for lupus. This could help doctors better predict which therapies will work best for each patient. This trial could open the door to a new class of treatments that target lupus at the molecular level.

Hospital 36

Hospital Therapy Networking Management 36

Dermatology Times

MARCH 10, 2025

Panelists discuss the newer systemic treatment options for pediatric atopic dermatitis (AD), including tralokinumab, JAK inhibitors, and nemolizumab, focusing on their mechanisms of action, efficacy, and safety profiles in treating moderate to severe cases of the condition in children.

Dermatitis 53

Dermatitis Therapy Safety Treatments 53

US Dermatologt Partners

JUNE 1, 2024

In the ever-evolving landscape of psoriasis treatment, oral therapies continue to play a crucial role. 1 In an interview with Dermatology Times, Lockshin explained how far we have come in oral treatment options for psoriasis, the future outlook, and patient populations that benefit most from orals.

Therapy 41

Therapy Injections Safety Management 41

Dermatology Times

JUNE 2, 2024

James Song, MD, explains combination treatment efficacy, addresses comorbidities, and provides pearls to improve patient safety.

Dermatitis 52

Dermatitis Therapy Safety Treatments 52

The Dermatology Digest

JUNE 5, 2024

Top-line data from the 24-week vehicle-controlled treatment period are expected in mid-2025. The randomized, double-blind, vehicle-controlled trial will evaluate the safety and efficacy of once-daily VYN201 topical gel in three dose cohorts (1%, 2% and 3% concentrations) compared to vehicle for 24 weeks.

Safety 73

Safety Office Facials Therapy 73

The Dermatology Digest

JANUARY 29, 2025

Delgocitinib cream 20mg/g bested oral alitretinoin for the treatment of chronic hand eczema, according to the Phase 3 DELTA FORCE trial. The topical pan-Janus kinase (JAK) inhibitor demonstrated superior treatment effects, quality of life improvements, and a more favorable safety profile compared to oral alitretinoin over 24 weeks.

Eczema 36

Eczema Safety Dermatology Therapy 36

The Dermatology Digest

MARCH 9, 2025

The safety and efficacy of dupilumab in BP are currently under clinical investigation and have not been evaluated by any regulatory authority. During treatment, all patients underwent a protocol-defined OCS tapering regimen if control of disease activity was maintained. 40% achieved 90% reduction in disease severity compared to 10%.

Sustainability 36

Sustainability Hospital Clinic Dermatology 36

The Dermatology Digest

JULY 1, 2024

PYZCHIVA has been approved for the treatment of moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderately to severely active Crohn’s disease, and moderately to severely active ulcerative colitis.

Portfolios 74

Portfolios Safety Clinic Injections 74

New Age Spa Institute

NOVEMBER 20, 2024

Licenses like those for esthetics, cosmetology , and massage therapy give professionals the legal right to practice their craft and offer services to the public. Choosing Between Esthetics, Cosmetology & Massage Therapy One of the most common questions we hear is, “ What’s the difference between an esthetician and a cosmetologist?

Esthetics 52

Esthetics Therapy Continuing Education Continuous Education 52